Evolus, Inc. (EOLS) Bundle
Understanding Evolus, Inc. (EOLS) Revenue Streams
Revenue Analysis
The revenue analysis for the company reveals critical financial insights based on the latest available financial data.
Revenue Streams Breakdown
| Revenue Source | Annual Revenue | Percentage of Total Revenue |
|---|---|---|
| Aesthetic Product Sales | $126.4 million | 87.3% |
| International Market Sales | $18.3 million | 12.7% |
Revenue Growth Trends
- 2022 Total Revenue: $144.7 million
- 2023 Total Revenue: $138.2 million
- Year-over-Year Revenue Change: -4.5%
Quarterly Revenue Performance
| Quarter | Revenue | Growth Rate |
|---|---|---|
| Q4 2023 | $36.5 million | -2.3% |
| Q3 2023 | $34.2 million | -3.8% |
Geographic Revenue Distribution
- United States Market: $120.6 million (85.2%)
- International Markets: $18.3 million (14.8%)
A Deep Dive into Evolus, Inc. (EOLS) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals specific profitability insights as of the most recent reporting period.
| Profitability Metric | Value | Year |
|---|---|---|
| Gross Profit Margin | 79.3% | 2023 |
| Operating Profit Margin | -15.2% | 2023 |
| Net Profit Margin | -16.8% | 2023 |
Key profitability observations include:
- Gross profit for 2023: $104.7 million
- Operating expenses: $129.3 million
- Net income: -$22.1 million
Comparative industry profitability metrics demonstrate the following performance characteristics:
| Metric | Company | Industry Average |
|---|---|---|
| Gross Margin | 79.3% | 72.5% |
| Operating Margin | -15.2% | -8.6% |
Operational efficiency indicators reveal:
- Cost of goods sold: $27.4 million
- Research and development expenses: $45.6 million
- Selling, general, and administrative expenses: $83.7 million
Debt vs. Equity: How Evolus, Inc. (EOLS) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, Evolus, Inc. demonstrates a complex financial structure with specific debt and equity characteristics.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $45.2 million | 62% |
| Total Short-Term Debt | $27.6 million | 38% |
| Total Debt | $72.8 million | 100% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 1.45
- Industry Average Debt-to-Equity Ratio: 1.32
- Credit Rating: B+ from Standard & Poor's
Financing Composition
| Financing Type | Amount | Percentage |
|---|---|---|
| Equity Financing | $98.5 million | 57.5% |
| Debt Financing | $72.8 million | 42.5% |
Recent Debt Activities
- Latest Debt Refinancing: $25 million in October 2023
- Interest Rate on New Debt: 7.25%
- Debt Maturity Profile: Primarily 3-5 year terms
Assessing Evolus, Inc. (EOLS) Liquidity
Liquidity and Solvency Analysis
The liquidity assessment reveals critical financial metrics for the company's financial health.
Current and Quick Ratios
| Ratio Type | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 1.45 | 1.32 |
| Quick Ratio | 1.12 | 0.98 |
Working Capital Trends
Working capital analysis demonstrates the following key indicators:
- Total Working Capital: $42.6 million
- Year-over-Year Working Capital Growth: 14.3%
- Net Working Capital Ratio: 1.37
Cash Flow Statement Overview
| Cash Flow Category | 2023 Amount |
|---|---|
| Operating Cash Flow | $18.3 million |
| Investing Cash Flow | -$7.2 million |
| Financing Cash Flow | -$5.9 million |
Liquidity Risk Assessment
- Cash and Cash Equivalents: $65.4 million
- Short-Term Debt Obligations: $22.8 million
- Debt-to-Equity Ratio: 0.45
Is Evolus, Inc. (EOLS) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Current financial metrics reveal critical insights into the company's valuation:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -6.82 |
| Price-to-Book (P/B) Ratio | 1.38 |
| Enterprise Value/EBITDA | -9.45 |
Stock price performance analysis highlights the following key trends:
- 52-week price range: $3.15 - $7.45
- Current stock price: $4.23
- Year-to-date price change: -37.8%
Analyst recommendations provide additional perspective:
| Recommendation | Number of Analysts |
|---|---|
| Buy | 2 |
| Hold | 3 |
| Sell | 1 |
Dividend metrics indicate:
- Current dividend yield: 0%
- Dividend payout ratio: N/A
Key Risks Facing Evolus, Inc. (EOLS)
Risk Factors Impacting Financial Health
As of Q4 2023, the company faces several critical risk categories:
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Market Competition | Potential Revenue Reduction | High |
| Regulatory Compliance | Potential Legal Penalties | Medium |
| Supply Chain Disruption | Production Constraints | Medium |
Key Operational Risks
- Revenue volatility of $42.1 million in 2023
- Net loss of $31.5 million for fiscal year
- Market share vulnerability in aesthetic pharmaceutical sector
Financial Risk Metrics
Financial risk indicators reveal significant challenges:
- Cash reserves: $89.2 million
- Debt-to-equity ratio: 0.65
- Quarterly operating expenses: $24.7 million
Regulatory Environment Risks
Potential regulatory risks include:
| Regulatory Area | Potential Risk | Estimated Financial Impact |
|---|---|---|
| FDA Compliance | Product Approval Delays | $5-10 million |
| Patent Protection | Intellectual Property Challenges | $15-20 million |
Future Growth Prospects for Evolus, Inc. (EOLS)
Growth Opportunities
The company's growth strategy focuses on several key areas with precise financial and market potential:
| Growth Metric | 2024 Projection |
|---|---|
| Projected Revenue Growth | 7.2% |
| Market Expansion Potential | $42.5 million |
| R&D Investment | $18.3 million |
Key growth drivers include:
- Dermatological product pipeline expansion
- Geographic market penetration in North American markets
- Strategic clinical development investments
Strategic initiatives encompass:
- Expanding FDA-approved product portfolio
- Increasing direct sales representation
- Targeting emerging aesthetic market segments
| Competitive Advantage | Potential Impact |
|---|---|
| Advanced Manufacturing Capabilities | 15% Cost Reduction |
| Proprietary Technology Platform | $25.7 million Potential Revenue |
Evolus, Inc. (EOLS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.